$RNAC News

Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target

Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments

Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40

Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25

Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target

Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target

Cartesian Therapeutics shares are trading higher after the company reported its Q4 financial results.

Cartesian Therapeutics shares are trading higher after the company reported its Q4 financial results.

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M

Insights into Cartesian Therapeutics Q4 Earnings

Cartesian Therapeutics to Participate in Upcoming Investor Conferences